Clinical trial
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
NCT06178159
Study timeline
Study start (actual)2023-11-28Date precision: day
Registry last updated2025-10-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
Pertuzumab InjectionDRUG · verified · RxNorm: pertuzumab Injection
ToripalimabDRUG · verified · RxNorm: toripalimab
Sponsors & collaborators
RemeGen Co., Ltd.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06178159 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.